Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
B Cell Chronic Lymphocytic Leukemia
Interventions
alemtuzumab
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ublituximab, TGR-1202, Chlorambucil
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Next-line ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
16
States / cities
Duarte, California • La Jolla, California • Stanford, California + 13 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Chlorambucil, Obinutuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Santa Barbara, California • Santa Monica, California • Whittier, California + 3 more
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Lymphoma
Interventions
Temsirolimus (CCI-779), Investigator's choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Chlorambucil
Drug
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
28
States / cities
Escondido, California • Whittier, California • New Britain, Connecticut + 25 more
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
chlorambucil, tablets, ofatumumab (GSK1841157) infusion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
30
States / cities
Sedona, Arizona • Tucson, Arizona • Murrieta, California + 25 more
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Chlorambucil, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 5 more
Conditions
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
Conditions
Chronic Lymphocytic Leukemia
Interventions
TGR-1202 + Obinutuzumab + Chlorambucil
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Huntsville, Alabama • Memphis, Tennessee
Active, not recruiting Phase 3 Interventional Results available

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
51
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 44 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Completed Phase 4 Interventional Results available

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691
Conditions
Uveitis
Interventions
fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Conditions
Non-Hodgkin's Lymphoma, Cancer
Interventions
Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico